about
The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infectionEvidence of Sexual Transmission of Zika VirusGag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness lossGeographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysisUse of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-UpCorrection: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-AnalysisCyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates.Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data.Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patientsVirological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA loadBaseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novaviPlasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infectionsNational sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesPredictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patientsTransmitted drug resistance in French HIV-2-infected patients.Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravirNNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to MaravirocIn vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study.In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo)Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patientsR57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe.Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.
P50
Q24318267-44646789-FF41-4764-AA44-C0AE8A7575DEQ28274810-634956CA-722B-45DB-9EFF-2311D38BFBE6Q28474984-4A996FEA-5A12-4424-BAD5-E60C0EB67AF2Q28545866-04CA8E1C-9CCE-42BF-A0DB-742FBB162350Q28546894-EBEC8F26-F637-48C8-B029-D5DBF86E673EQ28547717-A8A022C0-D634-4947-A6D4-C7853AB25E35Q30400372-07265C58-6D21-4F7A-95DE-0A704AE88B26Q30920685-7F412A54-9EB0-46BB-935A-DE3CC8DD5653Q33417236-79007789-2BCC-4EA5-B70D-466249590B26Q33558937-C3127697-EF18-40A6-AEB6-068E8064ACBEQ33769950-8EFFB61F-91D0-447D-BA9A-409ED47172E5Q34041529-2B4D1F01-E7E7-47C9-8C09-9D65DD50969EQ34045403-63216190-25A5-4252-833E-981D6E0E9521Q34058765-9E3A77C5-ECC1-41AB-8B7D-9E54F0DAFEBFQ34108713-713B1454-6172-4A57-B020-1F654D60F97CQ34109417-C605B74A-BE8D-43E9-9C9D-9B72C80D8C09Q34199460-83493E2C-AB20-4EA3-AD1F-1105118AEDD2Q34353387-05A28508-F6E3-47F2-8090-637E017396E9Q34387349-99958089-61AD-4081-862A-E7F42C2E80DFQ34562253-D9744071-5753-4BD8-A943-95BBC6B9D57CQ34563005-22900DE7-474A-41B2-BC99-EF3A9CE6CF7DQ34634839-32C7E0C8-BA25-4EA9-99A1-73742EF1EBA6Q34675595-4CEB6CCD-23FD-4345-AB29-999075B48DCCQ34737268-87F4D9A2-3A10-4D95-B786-9E170110D0C2Q34989105-4EA745FD-8359-4633-9A3E-4BBFFA3EC182Q34992731-996D198F-49E9-4A9E-BB68-80A76973E37DQ35206272-B2367E02-97EC-4783-A171-F91BD2547B72Q35589798-98526655-1C31-4E4D-96E2-8CCEDB2BFB1AQ35662019-50E0570D-E9EC-49CC-A6C8-92261754A7C8Q35666480-F900E3AA-03D2-4A58-BECB-247B1FD0971FQ35738681-60137F0E-4872-4ACA-9D80-8E07534BDCAAQ36289927-5C3951BB-4EAF-4F51-90C3-C1572A17C51BQ36538702-1D044E07-FDB0-40C4-ACA3-E0E37812715CQ36558452-9AC4D885-91E2-47D5-8BF8-11051CBA9245Q36785804-9814B5B2-71F6-4C65-9767-0D6DCA186233Q36870850-596F4CFE-137A-4A1D-862A-4E7A2FEA22E8Q36880577-323F0AE7-5352-4D44-A219-9A3783BC72EDQ38083487-F8C17D2F-BEBB-4767-A64F-C2DC91503229Q38657557-329A7F38-E971-4E29-9EA5-16A26350DE3FQ38682063-3D727004-F26A-4E5C-A90B-ED478BA2A7B4
P50
name
Diane Descamps
@ast
Diane Descamps
@en
Diane Descamps
@nl
type
label
Diane Descamps
@ast
Diane Descamps
@en
Diane Descamps
@nl
prefLabel
Diane Descamps
@ast
Diane Descamps
@en
Diane Descamps
@nl
P214
P21
P214
P31
P7859
viaf-193855419